| Disease | Micro RNA | Tissue/ Cell line | MicroRNA regulation | Targeted Member | More Details | References |
|---|---|---|---|---|---|---|
| Gastric cancer | hsa-miR-106a | Gastric cancer tissue | Up | FAS | MicroRNA-106a acts as an oncogene through down-regulating FAS in gastric cancer involving in promotion of cell growth and invasion. | Zhu et al., 2016 |
| Non-small cell lung cancer | hsa-miR-16 | Lung | Down | BCL 2 | Overexpression of miR-16 enhances paclitaxel induced apoptotic cell death by inhibiting anti-apoptotic protein Bcl-2. | Chatterjee et al., 2015 |
| Non-small cell lung cancer | hsa-miR-17 | Lung | Down | BECLIN 1 | Upregulation of miR-17 decreases cytoprotective autophagy by down-regulating the expression of Beclin-1. | Chatterjee et al., 2015 |
| Hepatocellular carcinoma | hsa-miR-193b | Hepatocyte | Down | MCL1 | Mcl-1 is the direct target of hsa-miR-193b and overexpression of hsa-miR-193b increased cancer cell sensitivity via caspase dependent apoptosis pathway. | Yin et al., 2015 |
| Atherosclerosis | hsa-miR-497 | HUVEC | Up | BCL2 | MiR-497 plays an important role in the development of atherosclerosis by inducing apoptosis via caspase3 pathway. | Wu et al., 2016 |
| Atherosclerosis | hsa-miR-497 | HUVEC | Up | CCND2 | MiR-497 significantly inhibits cell proliferation by arresting the cell cycle through the CCND2 protein and induces apoptosis through the caspase3 pathway. | Wu et al., 2016 |